Literature DB >> 22052540

MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma.

Eri Hiroki1, Fumihiko Suzuki, Jun-Ichi Akahira, Satoru Nagase, Kiyoshi Ito, Jun-Ichi Sugawara, Yasuhiro Miki, Takashi Suzuki, Hironobu Sasano, Nobuo Yaegashi.   

Abstract

Endometrial serous adenocarcinoma (ESC) is aggressive and carries a poor prognosis. p53 is frequently mutated in ESC. microRNAs (miRNAs) are a direct p53 target and have been implicated in cancer cell behavior. In this study, we compared miRNA expression levels in ESC with the levels in endometrial endometrioid adenocarcinoma (EEC) and normal endometria. Six miRNAs were identified as having aberrant down-regulation specific to ESC with miR-34b being most pronounced. miR-34b was found to have promoter hypermethylation, which when reversed, restored miR-34b expression in the cell lines treated with 5-aza-2' deoxycytidine (DAC). Ectopic expression of miR-34b in turn inhibited cell growth, migration and most notably invasion. Our findings suggest a relationship among p53 mutation, miR-34b promoter methylation and tumor cell behavior. These effects are likely mediated by the downstream target of miR-34b, the proto-oncogene mesenchymal-epithelial transition factor (MET), a known prognostic factor in endometrial carcinomas. The expression of MET was reduced following the restoration of miR-34b in cell lines. In summary, our data suggest that miR-34b plays a role in the molecular pathogenesis of endometrial cancer.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22052540     DOI: 10.1002/ijc.27345

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

1.  Recent advances in research on epigenetic alterations and clinical significance of para-aortic lymphadenectomy in endometrial cancer: an introduction.

Authors:  Noriaki Sakuragi
Journal:  Int J Clin Oncol       Date:  2013-02-20       Impact factor: 3.402

2.  Fifty-Hertz Magnetic Field Affects the Epigenetic Modulation of the miR-34b/c in Neuronal Cells.

Authors:  Claudia Consales; Claudia Cirotti; Giuseppe Filomeni; Martina Panatta; Alessio Butera; Caterina Merla; Vanni Lopresto; Rosanna Pinto; Carmela Marino; Barbara Benassi
Journal:  Mol Neurobiol       Date:  2017-10-16       Impact factor: 5.590

3.  Analysis of APOBEC3A/3B germline deletion polymorphism in breast, cervical and oral cancers from South India and its impact on miRNA regulation.

Authors:  Sundaramoorthy Revathidevi; Mayakannan Manikandan; Arunagiri Kuha Deva Magendhra Rao; Vilvanathan Vinothkumar; Ganesan Arunkumar; Kottayasamy Seenivasagam Rajkumar; Rajendran Ramani; Ramamurthy Rajaraman; Chandrasekar Ajay; Arasambattu Kannan Munirajan
Journal:  Tumour Biol       Date:  2016-05-07

Review 4.  MicroRNAs in gynecological cancers: Small molecules with big implications.

Authors:  Sanjeev K Srivastava; Aamir Ahmad; Haseeb Zubair; Orlandric Miree; Seema Singh; Rodney P Rocconi; Jennifer Scalici; Ajay P Singh
Journal:  Cancer Lett       Date:  2017-05-24       Impact factor: 8.679

Review 5.  MicroRNAs in endometrial cancer.

Authors:  Kouji Banno; Megumi Yanokura; Iori Kisu; Wataru Yamagami; Nobuyuki Susumu; Daisuke Aoki
Journal:  Int J Clin Oncol       Date:  2013-02-05       Impact factor: 3.402

6.  MicroRNA-200b is overexpressed in endometrial adenocarcinomas and enhances MMP2 activity by downregulating TIMP2 in human endometrial cancer cell line HEC-1A cells.

Authors:  Yinmei Dai; Wei Xia; Tao Song; Xueting Su; Jie Li; Shaohua Li; Ying Chen; Wei Wang; Hongmei Ding; Xuemei Liu; Hui Li; Qiang Zhao; Ningsheng Shao
Journal:  Nucleic Acid Ther       Date:  2012-12-03       Impact factor: 5.486

7.  MicroRNA-423 promotes proliferation, migration and invasion and induces chemoresistance of endometrial cancer cells.

Authors:  Jie Li; Huijie Sun; Ting Liu; Jian Kong
Journal:  Exp Ther Med       Date:  2018-09-07       Impact factor: 2.447

8.  MicroRNA-34a is dispensable for p53 function as teratogenesis inducer.

Authors:  Eyal Mor; Lin He; Arkady Torchinsky; Noam Shomron
Journal:  Arch Toxicol       Date:  2014-03-13       Impact factor: 5.153

9.  MiR-34b is associated with clinical outcome in triple-negative breast cancer patients.

Authors:  Marek Svoboda; Jiri Sana; Martina Redova; Jiri Navratil; Marketa Palacova; Pavel Fabian; Ondrej Slaby; Rostislav Vyzula
Journal:  Diagn Pathol       Date:  2012-03-22       Impact factor: 2.644

10.  Long non-coding RNA DLEU2 drives EMT and glycolysis in endometrial cancer through HK2 by competitively binding with miR-455 and by modulating the EZH2/miR-181a pathway.

Authors:  Peixin Dong; Ying Xiong; Yosuke Konno; Kei Ihira; Noriko Kobayashi; Junming Yue; Hidemichi Watari
Journal:  J Exp Clin Cancer Res       Date:  2021-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.